Delpor continues to strengthen its expertise in drug delivery with the addition of the former CEO of Glaxo and Alza to its Board of Directors.
SAN FRANCISCO, CA, January 19, 2012 – Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery of antipsychotics and biologics, today announced that Dr. Ernest Mario has joined the company’s Board of Directors.
“It is a big honor and a privilege that Ernie has joined our Board,” said Tassos Nicolaou, President and CEO of Delpor. “Ernie brings a wealth of experience in R&D, pharmaceutical product development, drug delivery, and corporate strategy. He is a perfect fit for our already strong and diverse Board of Directors, and I am certain that his contributions will have a positive and meaningful impact on our company. All of us at Delpor are looking forward to working with and learning from Ernie.”
Dr. Mario has served as CEO, Chairman, and Director at a variety of large life sciences companies where he has created billions of dollars in shareholder value. From 1989 to 1993, he served as Chief Executive of Glaxo, then the second-largest drug company in the world. After leaving Glaxo, he became Chairman and CEO of Alza Corporation, a major drug delivery company sold to Johnson & Johnson for $10.5 Billion in 2001. Dr. Mario subsequently served as Chairman and CEO of Reliant Pharmaceuticals, which was sold to GlaxoSmithKline in 2007 for $1.65 Billion. He currently is Chairman and CEO of Capnia, a private pharmaceutical company developing novel therapeutic products to treat migraine and allergic rhinitis using a proprietary gas delivery system. He is also a Venture Partner with Pappas Ventures and serves on a number of corporate boards. Dr. Mario is active in numerous educational and healthcare organizations. He is Chairman of the American Foundation for Pharmaceutical Education, a Director of the Gladstone Foundation, and past Chairman of the Duke University Health System. He holds honorary doctorates from the University of Rhode Island and Rutgers University, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy.
About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of antipsychotics (in order to improve medication adherence, tolerance, and safety) as well as delivery of biologics in order to improve patient safety and convenience. The company’s lead products include 3-month formulations of Risperidone, Paliperidone, and Interferon-alpha. Additional information about the company can be found at www.delpor.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Tassos Nicolaou, President and CEO